# Advancing Precision in Cancer Diagnostics

## with Hematologic Molecular Profiling

**Next-generation sequencing of DNA, RNA, cfDNA, and cfRNA**

Comprehensive genomic profiling enables the detection and differentiation of driver and sub-clonal mutations, determines prognosis and identifies targeted therapies for personalized medicine.

### GTC-Hematology Profile PLUS™

GTC-Hematology Plus combines expression and fusion with mutation analysis in DNA and RNA. This is a comprehensive evaluation of all hematologic neoplasms. However, it is especially recommended for:

- All types of Leukemias
- All types of Lymphomas
- All types of Myelomas
- Includes IgVH mutation status
- Viral EBV testing
- Chromosomal abnormalities, translocations and gene amplifications
- T-cell & B-cell clonality analysis
- HLA genotyping




## REDUCE YOUR TIME TO TREATMENT

**Results in 5-10 days for DNA and RNA**

**Precision Diagnosis, Classification and Advanced Treatment. Order today!**

### Liquid Trace™ Hematology

- A pan-cancer highly sensitive test evaluating 284 cfDNA genes and >1600 cfRNA genes
- Can be used for diagnoses, classification of all types of hematological malignancies, evaluating the host immune response, and identifying biomarkers for predicting response to various therapies
- Replacement for bone marrow aspirations and biopsy
- Monitoring therapy and response
- Detection of minimal residual disease (MRD)
- T-cell & B-cell clonality analysis
- HLA genotyping

### GTC-Hematology Profile™

This test is designed to profile the molecular abnormalities of 284 DNA genes associated with various hematologic neoplasms including:

- Myelodysplastic Syndrome (MDS)
- Myeloproliferative Neoplasms (MPN)
- Distinguish Clonal Hematopoiesis of Indeterminate Potential (CHIP)
- VEXAS Disease

**Do your patients want to avoid a bone marrow biopsy? Is a bone marrow biopsy necessary?**

**Investigating cytopenia with liquid biopsy vs. invasive bone marrow biopsy**

The Liquid Trace Hematology Profile is a great alternative to performing a bone marrow biopsy on individuals that present with cytopenia, for monitoring therapy and early detection of relapse.

GENOMIC® TESTING COOPERATIVE

### NY State Approved, Medicare Covered, and CE-IVD Marked

All GTC Hematology profiles are covered by Medicare and reimbursed by commercial insurances. To learn more contact: gtc@genomictestingcooperative.com

# Advancing Precision in Cancer Diagnostics

## with Solid Tumor Molecular Profiling

Genomic Testing Cooperative offers comprehensive next generation sequencing of DNA and RNA for solid tumors including cancers of the lung, pancreas, brain, colon, breast, ovary, endometrium, thyroid, head and neck, and soft tissue (sarcoma and GIST).

Our assays cover all clinically relevant genes including tumor mutation burden (TMB), MSI, HRD, fusion/translocations, copy number variation, amplification, and deletions.

Our reports provide full interpretation and presentation of clinical relevance for diagnosis, therapy, prognosis, heterogeneity and potential clinical trials.



### GTC- Solid Tumor Profile PLUS™

- Tests for abnormalities in 434 DNA genes and >1600 RNA genes
- A pan-tumor assay that can detect all cancer types
- Includes detection of single nucleotide variation, copy number variation, expression, known and novel fusions, exon skipping, alternative splicing
- Viral HPV testing
- Detect Cancer of Unknown Primary (CUP)
- T-cell & B-cell clonality analysis
- HLA genotyping

**REDUCE YOUR TIME TO TREATMENT**

**Results in 5-10 days for DNA and RNA**




### Liquid Trace™ Solid Tumor

- A pan-cancer highly sensitive test evaluating 284 cfDNA genes and >1600 cfRNA genes
- Can be used for diagnoses, evaluating the host immune response, and identifying biomarkers for predicting response to various therapies.
- Can reduce the need for tissue biopsies for certain cancer patients, especially when obtaining tissue from the tumor is difficult.
- Viral HPV testing
- T-cell & B-cell clonality analysis
- HLA genotyping

### GTC- Solid Tumor Profile™

- Profiles the molecular abnormalities in various solid tumors by analyzing the DNA of 434 genes, covering all exons
- Detects microsatellite instability (MSI), tumor mutation burden (TMB) and homologous recombination deficiency (HRD)
- Amplification in various genes can be detected
- Results provide prognosis, aid in therapeutic approach and predict response to therapy
- Useful for very small samples

### About Genomic Testing Cooperative, LCA

Genomic Testing Cooperative (GTC) is a privately-owned molecular testing company located in Irvine, CA. Dr. Maher Albitar established GTC, an independent NGS laboratory using state-of-the-art innovation in next generation sequencing and machine/deep learning. GTC operates based on a cooperative (Co-Op) business model, offering its patron members a full suite of comprehensive genomic profiling utilizing next generation sequencing for hematologic and solid tumors. For more information, please visit GTC's website: GenomicTestingCooperative.com

### NY State Approved, Medicare Covered, and CE-IVD Marked

All GTC Solid Tumor Profiles are covered by Medicare and reimbursed by commercial insurances.

To learn more contact:


Genomic Testing Cooperative, LCA
175 Technology Dr, Suite 100, Irvine, CA 92618
Tel: 1-949-540-9421 | Fax: 1-949-301-9719
Website: genomictestingcooperative.com
e-mail: gtc@genomictestingcooperative.com